Tarsus Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Tarsus Pharmaceuticals's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 32% to $17,447,000. Profit margin reached -779%. Total operating expenses were $159,012,000.
Profit Margin
| 2018 | 0 | -1.31M | |
|---|---|---|---|
| 2019 | 0 | -4.67M | |
| 2020 | 0 | -26.81M | |
| 2021 | 57.02M | -13.82M | -24.25% |
| 2022 | 25.81M | -62.09M | -240.51% |
| 2023 | 17.44M | -135.89M | -778.89% |
TARS Income Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Revenue | 17.44M | 25.81M | 57.02M | 0 | 0 | 0 |
Cost of revenue | 1.59M | 955K | 2.07M | 246K | 74K | 0 |
Gross profit | 15.85M | 24.86M | 54.95M | -246K | -74K | 0 |
Operating exp. | ||||||
Research and development | 50.31M | 42.62M | 41.71M | 18.82M | 3.16M | 901K |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 159.01M | 87.57M | 67.10M | 26.99M | 4.29M | 1.35M |
Operating income | -143.15M | -62.71M | -12.15M | -26.99M | -4.29M | -1.35M |
Other income (expenses), net | 7.26M | 617K | -1.61M | 188K | -371K | 32K |
Income before tax | -135.89M | -62.09M | -13.77M | -26.81M | -4.66M | -1.31M |
Income tax expense | 0 | -4K | 55K | 1K | 1K | 1K |
Net income | -135.89M | -62.09M | -13.82M | -26.81M | -4.67M | -1.31M |
Earnings per share | ||||||
Basic EPS | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
Diluted EPS | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Data source | Data source | Data source | Data source |